Le Lézard
Classified in: Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast

TransAct Technologies Reports Preliminary First Quarter 2024 Financial Results


TransAct Technologies Incorporated (Nasdaq: TACT) ("TransAct" or the "Company"), a global leader in software-driven technology and printing solutions for high-growth markets, today reported preliminary results for the first quarter ended March 31, 2024.

"We have continued confidence in our core product offerings and our ability to win new customers in new deployment situations across a number of verticals, with eight new logos added to our BOHA! platform in the quarter," said John Dillon, Chief Executive Officer of TransAct. "We are optimistic about the future of TransAct as an agile, transaction validation platform providing tailored solutions to our customers and believe there is significant opportunity in both the near and long-term to target new use cases with our existing products and to enter new markets further down the road."

First Quarter 2024 Financial Highlights

2024 Financial Outlook

Our outlook for non-GAAP adjusted EBITDA is presented only on a non-GAAP basis because not all of the information necessary for a quantitative reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable GAAP financial measure is available without unreasonable effort, primarily due to uncertainties relating to the occurrence or amount of these adjustments that may arise in the future. If one or more of the currently unavailable items is applicable, some items could be material, individually or in the aggregate, to GAAP reported results.

2024 First Quarter Conference Call and Webcast

TransAct is hosting a conference call and webcast today, May 7, 2024, beginning at 8:30 a.m. ET to discuss the Company's preliminary first quarter 2024 results and other matters. Both the call and the webcast are open to the general public. The conference call number is 877-704-4453 and the conference ID number is 13746173 (domestic or international). Please call ten minutes prior to the presentation to ensure that you are connected.

Interested parties may also access the conference call live on the Internet at www.transact-tech.com (select "Company" followed by "Investor Relations" followed by "Events & Presentations"). Approximately two hours after the call has concluded, an archived version of the webcast will be available for replay at the same location.

Non-GAAP Financial Measures

TransAct is providing certain non-GAAP financial measures because the Company believes that these measures are helpful to investors and others in assessing the ongoing nature of what the Company's management views as TransAct's core operations. EBITDA and adjusted EBITDA provide the Company with an understanding of one aspect of earnings before the impact of investing and financing charges and income taxes. The Company believes that these non-GAAP financial measures provide relevant and useful information to an investor evaluating the Company's operating performance because these measures are: (i) widely used by investors to measure a company's operating performance without regard to items that do not reflect the Company's ongoing operations and are excluded from the calculation of such measures; (ii) used as financial measurements by lenders and other parties to evaluate creditworthiness; and (iii) used by the Company's management for various purposes including strategic planning and forecasting and assessing financial performance. The presentation of this non-GAAP information is not considered superior to or a substitute for, and should be read in conjunction with, the financial information prepared in accordance with GAAP.

EBITDA is defined as net (loss) income before net interest expense, income taxes, depreciation, and amortization. A reconciliation of EBITDA to net (loss) income, the most comparable GAAP financial measure, can be found attached to this release.

Adjusted EBITDA is defined as net (loss) income before net interest (income) expense, income taxes, depreciation and amortization and is adjusted for (1) share-based compensation and (2) any other items, when they occur, that we believe do not reflect the ordinary earnings of the Company's ongoing business. The Company adjusts EBITDA for share-based compensation because the Company considers share-based compensation to be a non-cash expense similar to depreciation and amortization. A reconciliation of adjusted EBITDA to net (loss) income, the most comparable GAAP financial measure, can be found attached to this release.

About TransAct Technologies Incorporated

TransAct Technologies Incorporated is a global leader in developing and selling software-driven technology and printing solutions for high-growth markets including food service, casino and gaming, and POS automation. The Company's solutions are designed from the ground up based on customer requirements and are sold under the BOHA!tm, AccuDatetm, EPICENTRAL®, Epic and Ithaca® brands. TransAct has sold over 3.9 million printers, terminals and other hardware devices around the world and is committed to providing world-class service, spare parts, and accessories to support its installed product base. Through the TransAct Services Group, the Company also provides customers with a complete range of supplies and consumable items both online at http://www.transactsupplies.com and through its direct sales team. TransAct is headquartered in Hamden, CT. For more information, please visit http://www.transact-tech.com or call (203) 859-6800.

©2024 TRANSACT Technologies Incorporated. All rights reserved. TransAct®, BOHA!tm, AccuDatetm, Epic Edge®, EPICENTRAL® and Ithaca® are trademarks of TransAct Technologies Incorporated.

Cautionary Statement Regarding Preliminary Financial Information

The Company has prepared the preliminary financial information set forth below on a materially consistent basis with its historical financial information and in good faith based upon its internal reporting as of and for the three months ended March 31, 2024. This financial information is preliminary and is thus inherently uncertain and subject to change as the Company finalizes its financial results and related review for the three months ended March 31, 2024. During the course of the preparation of the Company's consolidated financial statements and related notes as of and for the three months ended March 31, 2024, the Company may identify items that could cause its final reported results to be materially different from the preliminary financial information set forth above. As a result, there can be no assurance that the Company's final results for this period will not differ from the preliminary financial information.

This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with GAAP. In addition, this preliminary financial information is not necessarily indicative of the results to be achieved for any future period.

Forward-Looking Statements

Certain statements included in this press release may be forward-looking statements within the meaning of the U.S. federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements other than statements of historical fact. Forward-looking statements represent current views about possible future events and are often identified by the use of forward-looking terminology, such as "may", "will", "could", "expect", "intend", "estimate", "anticipate", "believe", "project", "plan", "predict", "design" or "continue", or the negative thereof, or other similar words. Forward-looking statements are subject to certain risks, uncertainties and assumptions. In the event that one or more of such risks or uncertainties materialize, or one or more underlying assumptions prove incorrect, actual results may differ materially from those expressed or implied by the forward-looking statements. Important factors and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include, but are not limited to, the following: the adverse effects of current economic conditions on our business, operations, financial condition, results of operations and capital resources, difficulties or delays in manufacturing or delivery of inventory or other supply chain disruptions, inflation and the Russia/Ukraine and Middle East conflicts, an inability of our customers to make payments on time or at all, diversion of management attention, a possible future reduction in the value of goodwill or other intangible assets, inadequate manufacturing capacity or a shortfall or excess of inventory as a result of difficulty in predicting manufacturing requirements due to volatile economic conditions, price increases or decreased availability of component parts or raw materials, exchange rate fluctuations, volatility of and decreases in trading prices of our common stock and the availability of needed financing on acceptable terms or at all; our ability to successfully develop new products that garner customer acceptance and generate sales, both domestically and internationally, in the face of substantial competition; our reliance on an unrelated third party to develop, maintain and host certain web-based food service application software and develop and maintain selected components of our downloadable software applications pursuant to a non-exclusive license agreement, and the risk that interruptions in our relationship with that third party could materially impair our ability to provide services to our food service technology customers on a timely basis or at all and could require substantial expenditures to find or develop alternative software products; our ability to successfully grow our business in the food service technology market; risks associated with the pursuit of strategic initiatives and business growth; general economic conditions; our dependence on contract manufacturers for the assembly of a large portion of our products in Asia; our dependence on significant suppliers; our ability to recruit and retain quality employees; our dependence on third parties for sales outside the United States; marketplace acceptance of new products; risks associated with foreign operations; the availability of third-party components at reasonable prices; price wars, supply chain disruptions or other significant pricing pressures affecting the Company's products in the United States or abroad; increased product costs or reduced customer demand for our products due to changes in U.S. policy that may result in trade wars or tariffs; our ability to protect intellectual property; and other risk factors identified and discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and other reports filed with the Securities and Exchange Commission. We caution readers not to place undue reliance on forward-looking statements, which speak only as of the date of this release. We undertake no obligation to publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events or other factors, except where we are expressly required to do so by applicable law.

- Financial tables follow-

TRANSACT TECHNOLOGIES INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Preliminary and Unaudited)

 

 

 

Three months ended
March 31,

 

2024

 

2023

 

(In thousands, except per share data)

 

 

 

 

Net sales

$10,687

 

$22,270

Cost of sales

5,063

 

10,015

Gross profit

5,624

 

12,255

 

 

 

 

Operating expenses:

 

 

 

Engineering, design and product development

1,966

 

2,269

Selling and marketing

2,083

 

2,757

General and administrative

2,876

 

3,416

 

6,925

 

8,442

Operating (loss) income

(1,301)

 

3,813

 

 

 

 

Interest and other income (expense):

 

 

 

Interest, net

48

 

(66)

Other, net

(60)

 

21

 

(12)

 

(45)

 

 

 

 

(Loss) income before income taxes

(1,313)

 

3,768

Income tax benefit (expense)

277

 

(629)

Net (loss) income

$(1,036)

 

$3,139

 

 

 

 

Net (loss) income per common share:

 

 

 

Basic

$(0.10)

 

$0.32

Diluted

$(0.10)

 

$0.31

 

 

 

 

Shares used in per share calculation:

 

 

 

Basic

9,972

 

9,930

Diluted

9,972

 

10,043

 

SUPPLEMENTAL INFORMATION ? SALES BY MARKET:

(Preliminary and Unaudited)

 

Three months ended
March 31,

 

2024

 

2023

 

(In thousands)

 

 

 

 

Food service technology

$3,300

 

$3,458

POS automation

651

 

1,797

Casino and gaming

5,696

 

15,811

TransAct Services Group

1,040

 

1,204

Total net sales

$10,687

 

$22,270

 

TRANSACT TECHNOLOGIES INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Preliminary and Unaudited)

 

 

 

 

March 31,

 

 

December 31,

 

 

2024

 

2023

Assets:

 

(In thousands)

Current assets:

 

 

 

 

Cash and cash equivalents

 

$10,631

 

$12,321

Accounts receivable, net

 

7,780

 

9,824

Inventories

 

19,171

 

17,759

Prepaid income taxes

 

352

 

322

Other current assets

 

931

 

773

Total current assets

 

38,865

 

40,999

 

 

 

 

 

Fixed assets, net

 

2,187

 

2,421

Right-of-use assets

 

1,371

 

1,602

Goodwill

 

2,621

 

2,621

Deferred tax assets

 

6,691

 

6,304

Intangible assets, net

 

50

 

88

Other assets

 

133

 

163

 

 

13,053

 

13,199

Total assets

 

$51,918

 

$54,198

 

 

 

 

 

Liabilities and Shareholders' Equity:

 

 

 

 

Current liabilities:

 

 

 

 

Revolving loan payable

 

$2,250

 

$2,250

Accounts payable

 

$4,226

 

4,431

Accrued liabilities

 

4,126

 

4,947

Lease liabilities

 

941

 

929

Deferred revenue

 

925

 

1,079

Total current liabilities

 

12,468

 

13,636

 

 

 

 

 

Deferred revenue, net of current portion

 

196

 

209

Lease liabilities, net of current portion

 

468

 

720

Other liabilities

 

215

 

219

 

 

879

 

1,148

Total liabilities

 

13,347

 

14,784

 

 

 

 

 

Shareholders' equity:

 

 

 

 

Common stock

 

140

 

140

Additional paid-in capital

 

57,249

 

57,055

Retained earnings

 

13,342

 

14,378

Accumulated other comprehensive loss, net of tax

 

(50)

 

(49)

Treasury stock, at cost

 

(32,110)

 

(32,110)

Total shareholders' equity

 

38,571

 

39,414

Total liabilities and shareholders' equity

 

$51,918

 

$54,198

 

 

 

 

 

TRANSACT TECHNOLOGIES INCORPORATED

RECONCILIATION OF NET (LOSS) INCOME TO EBITDA AND ADJUSTED EBITDA

NON-GAAP FINANCIAL MEASURES

(Preliminary and Unaudited)

 

 

Three Months Ended

 

 

March 31,

 

 

2024

 

2023

 

 

(In thousands)

 

 

 

 

 

Net (loss) income

 

$(1,036)

 

$3,139

 

 

 

 

 

Interest (income) expense, net

 

(48)

 

66

Income tax (benefit) expense

 

(277)

 

629

Depreciation and amortization

 

395

 

352

 

 

 

 

 

EBITDA

 

(966)

 

4,186

 

 

 

 

 

Share-based compensation expense

 

265

 

278

 

 

 

 

 

Adjusted EBITDA

 

$(701)

 

$4,464

 


These press releases may also interest you

at 11:10
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: